Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
Aidan A. Long(Harvard University), Stanley J. Szefler(Children's Hospital Colorado), Hubert Chen, Eva C. Guinan(Dana-Farber Cancer Institute), Gillis Carrigan, Abdelkader Rahmaoui, Kenneth J. Rothman(Boston University), Carlos Iribarren(Kaiser Permanente), Mary S. Bradley, Karin Rosén(Baylor College of Medicine), Mark D. Eisner(Royal Victoria Infirmary)
Cited by 222
Related Papers
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
Genome-wide meta-analyses identify multiple loci associated with smoking behavior
|Nature Genetics|2010|1.2k
Long-Term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma
|New England Journal of Medicine|2006|1.1k
An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2010|986
Pulmonary Dead-Space Fraction as a Risk Factor for Death in the Acute Respiratory Distress Syndrome
|New England Journal of Medicine|2002|898